We are live on ! Find out more
ANIP icon

ANI Pharmaceuticals
ANIP

230 hedge funds and large institutions have $1.35B invested in ANI Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 63 increasing their positions, 76 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 20

27% more capital invested

Capital invested by funds: $1.07B → $1.35B (+$284M)

12% more funds holding

Funds holding: 205 → 230 (+25)

0.16% more ownership

Funds ownership: 91.85% → 92.01% (+0.16%)

17% less repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 76

38% less call options, than puts

Call options by funds: $535K | Put options by funds: $863K

Holders
230
Holders Change
+25
Holders Change %
+12.2%
% of All Funds
3.08%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.05%
New
47
Increased
63
Reduced
76
Closed
20
Calls
$535K
Puts
$863K
Net Calls
-$328K
Net Calls Change
+$81K

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$12.6M
2
Aberdeen Group
Aberdeen Group
United Kingdom
+$10.8M
3
WP
Woodline Partners
California
+$9.94M
4
JP Morgan Chase
JP Morgan Chase
New York
+$9.24M
5
Citadel Advisors
Citadel Advisors
Florida
+$7.87M

Top Sellers

1
UBS Group
UBS Group
Switzerland
-$19.7M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$11.8M
3
Millennium Management
Millennium Management
New York
-$11M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$7.94M
5
Macquarie Group
Macquarie Group
Australia
-$6.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
126
Wellington Management Group
Massachusetts
$549K +$490K +8,206 New
IMRF
127
Illinois Municipal Retirement Fund
Illinois
$546K -$22.2K -371 -4%
T. Rowe Price Associates
128
T. Rowe Price Associates
Maryland
$542K +$47.8K +801 +11%
1CM
129
1492 Capital Management
Wisconsin
$528K -$17.6K -295 -4%
LSERS
130
Louisiana State Employees Retirement System
Louisiana
$522K -$11.9K -200 -3%
OAM
131
OP Asset Management
$505K +$451K +7,550 New
PCM
132
Penn Capital Management
Pennsylvania
$448K +$400K +6,696 New
New York State Common Retirement Fund
133
New York State Common Retirement Fund
New York
$437K -$69.2K -1,159 -15%
Envestnet Asset Management
134
Envestnet Asset Management
Illinois
$432K +$91.2K +1,527 +31%
YCM
135
Yousif Capital Management
Michigan
$422K -$8.18K -137 -2%
Allianz Asset Management
136
Allianz Asset Management
Germany
$415K +$370K +6,200 New
GCM
137
Graham Capital Management
Connecticut
$399K -$23.5K -393 -6%
QC
138
Quadrature Capital
United Kingdom
$394K +$352K +5,892 New
HNW
139
High Note Wealth
Minnesota
$388K – – –
BCM
140
Bayesian Capital Management
New York
$365K +$325K +5,447 New
HT
141
Headlands Technologies
Illinois
$359K +$249K +4,171 +348%
Neuberger Berman Group
142
Neuberger Berman Group
New York
$357K -$8.24K -138 -3%
ProShare Advisors
143
ProShare Advisors
Maryland
$355K -$73.6K -1,232 -19%
SFS
144
Sowell Financial Services
Arkansas
$352K +$314K +5,262 New
MUAMU
145
Mitsubishi UFJ Asset Management (UK)
United Kingdom
$335K +$299K +5,000 New
HWM
146
Hohimer Wealth Management
Washington
$334K +$14.8K +247 +5%
NRD
147
Nebula Research & Development
New York
$330K -$426K -7,125 -59%
MSRPS
148
Maryland State Retirement & Pension System
Maryland
$325K -$44.5K -745 -13%
ASRS
149
Arizona State Retirement System
Arizona
$323K -$2.99K -50 -1%
AB
150
Amalgamated Bank
New York
$322K +$538 +9 +0.2%
4 5
6
7 8

ANIP Hedge Fund Activity: Q1 2025 in Review

230 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q1 2025, worth a combined $1.35B — up 27% from $1.07B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new ANIP positions and 20 closed out — a net gain of 27 holders — while 63 added to existing stakes and 76 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $12.6M. The largest seller was UBS Group, cutting an estimated $19.7M.

  • 230 institutional investors held ANI Pharmaceuticals (ANIP) as of Q1 2025, up from 205 in Q4 2024.
  • Funds reported $1.35B of ANI Pharmaceuticals stock for Q1 2025, up 27% quarter-over-quarter.
  • 47 funds opened new ANI Pharmaceuticals positions in Q1 2025 and 20 closed out, a net change of +27 holders.
  • The largest ANI Pharmaceuticals buyer in Q1 2025 was Morgan Stanley, an estimated $12.6M added.
  • The largest ANI Pharmaceuticals seller in Q1 2025 was UBS Group, an estimated $19.7M sold.

Based on aggregated 13F filings for Q1 2025.